期刊文献+

抗肿瘤溶栓嵌合蛋白制备工艺研究

Studies on Preparation of Chimeric Proteins Possessing Anti-tumor and Thrombolytic
下载PDF
导出
摘要 对抗肿瘤溶栓嵌合蛋白在重组大肠杆菌中高效表达作了研究.以装液量、接菌量和初始pH值三因素设计正交试验,确定其最佳培养条件.结果表明:抗肿瘤溶栓嵌合蛋白制备工艺的最佳培养条件是装液量100 m L、接菌量2%、初始pH值7.5.在优化后的培养条件下,1 L发酵液可以得到0.987 mg蛋白,比优化前蛋白量提高了一倍,较高的表达量为进一步研究该蛋白的纯化和性质提供了基础. The high express of chimeric proteins possessing anti-tumor and thrombolytic in E.coli was studied. The optimum cultivating conditions were determined through orthogonal test of culture volume,seed dose and medium original pH value. Results showed that the optimum cultivating conditions for preparation of chimeric proteins possessing anti-tumor and thrombolytic were summarized as follows: culture volume is 100 m L,seed dose is 2%,medium original pH value is 7. 5. Under the optimum cultivating conditions,1 L fermented liquid can get 0. 987 mg protein,which was 1-fold of the initial protein porduction. The relative high protein porduction was helpful for further study on the purification and characterization of the protein.
作者 回晶 张庆岩 胡风庆 HUI Jing;ZHANG Qing-yan;HU Feng-qing(Laboratory of Biomaterials and Biopharmaceuticals,School of Life Sciences,Liaoning University;College of Light Industry,Liaoning University,shenyang 110036,China)
出处 《辽宁大学学报(自然科学版)》 CAS 2018年第2期170-173,共4页 Journal of Liaoning University:Natural Sciences Edition
基金 辽宁大学博士启动基金
关键词 恶性肿瘤 血栓 培养条件 正交试验 malignant tumor hrombosis cultivating conditions orthogonal design
  • 相关文献

参考文献4

二级参考文献26

  • 1JieYan Shou-FengZhao Ya-EeiMao Yi-HuiLuo.Effects of lactose as an inducer on expression of Helicobacter pylori rUreB and rHpaA, and Escherichia colirLTKA63 and rLTB[J].World Journal of Gastroenterology,2004,10(12):1755-1758. 被引量:2
  • 2何国庆,李春丽,阮晖,陈其新,陈正华.人β-防御素-3与植物甜蛋白Brazzein嵌合基因的合成及其在大肠杆菌中的表达[J].农业生物技术学报,2005,13(2):217-220. 被引量:6
  • 3李春丽,阮晖,陈正华,陈其新,何国庆.重组人β防御素3在大肠杆菌中的表达和活性分析[J].中国生物化学与分子生物学报,2005,21(5):705-708. 被引量:14
  • 4Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized neutropenic cancer patients [ J ]. J Clin Oncol,2006, 24:484 - 490.
  • 5Ruckles FR, Levine MN. Epidemiology of thrombosis in cancer [ J]. Acta Haematol,2002,106:6 - 12.
  • 6Sallah S,Wan JY,Nguyen NP. Venous thrombosis in patients with solid tumors : determination of frequency and characteristics [ J ]. Thromb Haemost,2002,87 ( 4 ) :575 - 579.
  • 7Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis [ J ]. Ann Intern Med, 1996,125:1 -7.
  • 8Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy:risk analysis using Medicare claims data [ J ]. Medicine (Baltimore) , 1999,78:285 - 291.
  • 9Heit JA, Silverstein MD, Mohr DN, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population- based, cohort Study [ J ]. Arch Intern Med, 1999,159:445 -453.
  • 10Sorensen HT,Mellemkjaer L,Olsen JH, et al. Prognosis of cancers associated with venous thromboembolism [ J ]. N Engl J Med, 2000,343 : 1846 - 1850.

共引文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部